Moderna price drops — what’s behind today’s move (December 23)

Traders Union
All News
Financial News
Moderna Slides 5.18% Today on News

Highlights

Moderna received regulatory approval in South Korea for its mRNA-based RSV vaccine, mRESVIA, further diversifying its vaccine portfolio beyond COVID-19.
CEPI awarded up to $54.3 million to Moderna to fund a Phase 3 trial for its H5 avian influenza vaccine, supporting late-stage development.
Moderna is undertaking a major restructuring and expanding global manufacturing, aiming to adapt to changing vaccine demand and ensure sustainable revenue.

Pipeline diversification expands amid regulatory wins and restructuring

Moderna recently secured regulatory approval in South Korea for its mRNA-based RSV vaccine, mRESVIA, expanding its product portfolio beyond COVID-19. The company was awarded up to $54.3 million by CEPI to fund a Phase 3 trial for its H5 avian influenza vaccine and is undergoing a major restructuring to adapt to shifting vaccine demand. Ongoing global manufacturing expansion and collaborations with prominent partners also support efforts to create a diversified and sustainable revenue stream.

Anton Kharitonov, expert at Traders Union, sees Moderna’s position above all major moving averages but warns this is not enough for long-term conviction. He highlights the overbought signals on RSI, CCI, and BBP as red flags, especially amid recent aggressive selling and a 5.18% daily drop. While the news of expanded vaccine approvals and new funding may seem positive, he cautions that restructuring and changing vaccine demand introduce uncertainty. Kharitonov stresses that downside risk prevails if $33 fails, with little support from short-term momentum. "Given stretched indicators and a sharp reversal, I remain cautious and see an elevated risk of further correction."

Viktoras Karapetjanc, expert at Traders Union, believes Moderna’s regulatory wins and global partnerships affirm confidence in its future business model. He sees diversified vaccine approvals and CEPI backing as catalysts for long-term revenue sustainability, despite shifts in daily price movement. Karapetjanc points out that the bullish structure remains intact as major averages support the trend and broader market sentiment favors further growth. He expects new collaborations to unlock multiple setups and sees further opportunity if price holds above $33. "With strategic wins and strong technical alignment, I expect further upside if momentum recovers above $35."

Parshwa Turakhiya, analyst, notes short-term sentiment is turning cautious after a sharp daily drop, despite earlier bullish momentum. He observes overbought oscillators now signaling a pause, while sellers have taken clear control for the session. Turakhiya emphasizes short-term traders should watch for either a bounce at $33 or a quick test of lower support if momentum fades. "I suggest waiting for stability near $33 before considering fresh entries — this is a pivotal level for short-term direction."

Overbought readings persist as intraday pressure dents bullish trend

Momentum favors the bulls on the daily chart, with MACD and ADX maintaining positive signals. RSI at 80.23, CCI at 176.22, and BBP at 5.69 demonstrate significant overbought conditions, while Stoch RSI echoes this with extreme readings. Despite overbought warnings, daily price action has turned lower, slipping 5.18% following a gap down at the open and now trading near intraday lows. Sellers dominate intraday sentiment, and even as the Awesome Oscillator remains bullish, shorter-term oscillators and momentum signals point to possible exhaustion.

Previously it was reported that MRNA continued its bullish momentum, trading firmly above key moving averages while nearing resistance as buyers dominated recent sessions. Technical signals showed mixed momentum — the MACD remained bullish, ADX indicated modest trend strength, and the RSI approached overbought territory, with multiple oscillators all flag overbought conditions and price consolidating just below key resistance.

Source of Data: MRNA Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.